Company Profile
Vistagen Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- VTGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.24 USD (+2.74%)
Close
Last updated: September 18, 2026
23M USD
Market cap
Why the stock is moving
The latest monitored company update is “Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder.” The corresponding closing-price reaction is not yet available.
Company overview
Intranasal Pherine Platform
Vistagen is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal therapies that modulate nose-to-brain neurocircuitry. Its pherine candidates are designed to produce therapeutic effects without requiring systemic absorption or direct uptake into the brain, potentially reducing adverse effects associated with conventional central nervous system drugs.
Fasedienol for Social Anxiety Disorder
Fasedienol is Vistagen's lead pherine candidate for the acute treatment of social anxiety disorder. The Phase 3 PALISADE-4 study did not meet its primary endpoint in the overall population, although post-hoc analyses identified a nominally significant signal in patients with very severe disease. An exploratory repeat-dose study produced similar subgroup observations, while the PALISADE-3 open-label extension continues to provide longer-term safety information.
Itruvone for Major Depressive Disorder
Itruvone is an intranasal pherine being developed for major depressive disorder. It is intended to engage nasal chemosensory pathways associated with mood regulation while avoiding the systemic exposure required by conventional antidepressants.
Refisolone for Menopausal Hot Flashes
Refisolone is an intranasal pherine candidate for moderate-to-severe vasomotor symptoms associated with menopause. The program is covered by an open US IND, and the FDA has issued a Study May Proceed letter.
Future catalysts
- FDA meeting during the third quarter of 2026 to discuss a potential registration-directed Phase 3 pathway for fasedienol in social anxiety disorder.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics, Inc. (VTGN) most recently closed at 0.24 USD, a +2.74% move versus the previous session.
What is the market cap of Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics, Inc. currently has a market capitalization of 23M USD on BioPharmSignal.
What does Vistagen Therapeutics, Inc. do?
Intranasal Pherine Platform Vistagen is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal therapies that modulate nose-to-brain neurocircuitry. Its pherine candidates are designed to produce therapeutic effects without requiring systemic absorption or direct uptake into the brain, potentially reducing adverse effects...
On which exchange is VTGN stock listed?
Vistagen Therapeutics, Inc. (VTGN) is associated with NASDAQ, United States, Biopharma.
What is PALISADE-4?
The Phase 3 PALISADE-4 study did not meet its primary endpoint in the overall population, although post-hoc analyses identified a nominally significant signal in patients with very severe disease.
Which conditions is Vistagen Therapeutics, Inc. targeting with PALISADE-4?
Intranasal Pherine Platform Vistagen is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal therapies that modulate nose-to-brain neurocircuitry. Its pherine candidates are designed to produce therapeutic effects without requiring systemic absorption or direct uptake into the brain, potentially reducing adverse effects...
How does Vistagen Therapeutics, Inc. describe recent progress with PALISADE-4?
FDA meeting during the third quarter of 2026 to discuss a potential registration-directed Phase 3 pathway for fasedienol in social anxiety disorder.
What is PALISADE-3?
An exploratory repeat-dose study produced similar subgroup observations, while the PALISADE-3 open-label extension continues to provide longer-term safety information.